Cellular immunotherapy for refractory hematological malignancies

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Reagan, John L ^a   Fast, Loren D ^a   Safran, Howard ^a   Nevola, Martha ^a   Winer, Eric S ^a   Castillo, Jorge J ^a   Butera, James N ^a   Quesenberry, Matthew I ^a   Young, Carolyn T ^a   Quesenberry, Peter J ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Acute myeloid leukemia; Cellular therapy; Cytokine release syndrome; Hematological malignancies; Immunotherapy; Non Hodgkin lymphoma

Indexed keywords

CHEMOKINE; CYTOKINE; DIPHENHYDRAMINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; LEUKOCYTE ANTIGEN; METHYLPREDNISOLONE; PARACETAMOL;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ARTICLE; BLOOD SAMPLING; BONE MARROW TOXICITY; BONE MARROW TRANSPLANTATION; CANCER IMMUNOTHERAPY; CD3+ T LYMPHOCYTE; CELL POPULATION; CELL THERAPY; CELL VACUOLE; CHIMERA; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL PROTOCOL; CYTOKINE RELEASE; CYTOKINE RELEASE SYNDROME; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; EFFECTOR CELL; ENGRAFTMENT; GENETIC ANALYSIS; GRAFT VERSUS HOST REACTION; HAPLOIDY; HAPLOIMMUNOSTORM; HEMATOLOGIC MALIGNANCY; HLA TYPING; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOLOGY; LEUKEMIA RELAPSE; LYMPHADENOPATHY; LYMPHOMA; MYELOABLATIVE CONDITIONING; NONHODGKIN LYMPHOMA; PATIENT MONITORING; PERIPHERAL BLOOD STEM CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN BLOOD LEVEL; RADIATION DOSE; TREATMENT OUTCOME; TUMOR IMMUNITY; WHOLE BODY RADIATION;

GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOTHERAPY; LEUKEMIA, MYELOID, ACUTE; REMISSION INDUCTION; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; STEM CELL TRANSPLANTATION;

EID: 84879039088     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-150     Document Type: Article

References (31)

1. Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA. SEER Cancer Statistics Review, 1975-2010. 2013, : , posted to the SEER web site.
2. Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, Wadleigh M, DeAngelo DJ, Stone RM, Sakamaki H, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009, 301(22):2349-2361. 10.1001/jama.2009.813, 3163846, 19509382.
3. Schmid C, Labopin M, Nagler A, Niederwieser D, Castagna L, Tabrizi R, Stadler M, Kuball J, Cornelissen J, Vorlicek J, et al. Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood 2012, 119(6):1599-1606. 10.1182/blood-2011-08-375840, 22167752.
4. Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, Durrant IJ, Luger SM, Marks DI, Franklin IM, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 2007, 109(3):944-950.
5. Stock W, Johnson JL, Stone RM, Kolitz JE, Powell BL, Wetzler M, Westervelt P, Marcucci G, DeAngelo DJ, Vardiman JW, et al. Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia. Cancer 2013, 119(1):90-98. 10.1002/cncr.27617, 22744771.
6. Kantarjian H, Thomas D, O'Brien S, Cortes J, Giles F, Jeha S, Bueso-Ramos CE, Pierce S, Shan J, Koller C, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004, 101(12):2788-2801. 10.1002/cncr.20668, 15481055.
7. Freytes CO, Zhang M-J, Carreras J, Burns LJ, Gale RP, Isola L, Perales M-A, Seftel M, Vose JM, Miller AM, et al. Outcome of Lower-Intensity Allogeneic Transplantation in Non-Hodgkin Lymphoma after Autologous Transplantation Failure. Biol Blood Marrow Transplant 2012, 18(8):1255-1264. 10.1016/j.bbmt.2011.12.581, 22198543.
8. Freytes CO, Loberiza FR, Rizzo JD, Bashey A, Bredeson CN, Cairo MS, Gale RP, Horowitz MM, Klumpp TR, Martino R, et al. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood 2004, 104(12):3797-3803. 10.1182/blood-2004-01-0231, 15280203.
9. Gupta V, Richards S, Rowe J. Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis. Blood 2013, 121(2):339-350. 10.1182/blood-2012-07-445098, 23165481.
10. Stewart F, Crittenden R, Lowry P, Pearson-White S, Quesenberry P. Long-term engraftment of normal and post-5-fluorouracil murine marrow into normal nonmyeloablated mice [see comments]. Blood 1993, 81(10):2566-2571.
11. Stewart FM, Zhong S, Wuu J, Hsieh C-C, Nilsson SK, Quesenberry PJ. Lymphohematopoietic Engraftment in Minimally Myeloablated Hosts. Blood 1998, 91(10):3681-3687.
12. Stewart FM, Zhong S, Lambert J-F, Colvin GA, Abedi M, Dooner MS, McAuliffe CI, Wang H, Hsieh C, Quesenberry PJ. Host marrow stem cell potential and engraftability at varying times after low-dose whole-body irradiation. Blood 2001, 98(4):1246-1251. 10.1182/blood.V98.4.1246, 11493477.
13. Lambert J-F, Colvin GA, Zhong S, Wang H, D'Hondt L, Abedi M, Frimberger AE, Stewart FM, Quesenberry PJ. H2-mismatched transplantation with repetitive cell infusions and CD40 ligand antibody infusions without myeloablation. Br J Haematol 2002, 119(1):155-163. 10.1046/j.1365-2141.2002.03801.x, 12358920.
14. Ballen KK, Becker PS, Emmons RVB, Fitzgerald TJ, Hsieh CC, Liu Q, Heyes C, Clark Y, Levy W, Lambert JF, et al. Low-dose total body irradiation followed by allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancy. Blood 2002, 100(2):442-450. 10.1182/blood.V100.2.442, 12091334.
15. Colvin GA, Berz D, Ramanathan M, Winer ES, Fast L, Elfenbein GJ, Quesenberry PJ. Nonengraftment haploidentical cellular immunotherapy for refractory malignancies: tumor responses without chimerism. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation 2009, 15(4):421-431.
16. Rubio M-T, Kim Y-M, Sachs T, Mapara M, Zhao G, Sykes M. Antitumor effect of donor marrow graft rejection induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: critical role for recipient-derived IFN-γ. Blood 2003, 102(6):2300-2307. 10.1182/blood-2002-12-3949, 12791660.
17. Reagan JL, Fast LD, Winer ES, Safran H, Butera JN, Quesenberry PJ. Nonengraftment haploidentical cellular therapy for hematologic malignancies. Adv Hematol 2012, 2012(2):784213. 3270515, 22312367.
18. Porter DL, Grupp SA, Kalos M, Loren AW, Lledo L, Gilmore J, Milone MC, Chew A, Levine BL, June CH. Chimeric Antigen Receptor T Cells Directed Against CD19 Induce Durable Responses and Transient Cytokine Release Syndrome in Relapsed, Refractory CLL and ALL. ASH Annual Meeting Abstracts 2012, 120(21):717.
19. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013, 368(16):1509-1518. 10.1056/NEJMoa1215134, 23527958.
20. Grupp SA, Porter DL, Teachey DT, Barrett DM, Chew A, Suppa E, Levine BL, Kalos M, June CH. CD19-Redirected Chimeric Antigen Receptor T (CART19) Cells Induce a Cytokine Release Syndrome (CRS) and Induction of Treatable Macrophage Activation Syndrome (MAS) That Can Be Managed by the IL-6 Antagonist Tocilizumab (toc). ASH Annual Meeting Abstracts 2012, 120(21):2604.
21. Guo M, Hu K-X, Yu C-L, Sun Q-Y, Qiao J-H, Wang D-H, Liu G-X, Sun W-J, Wei L, Sun X-D, et al. Infusion of HLA-mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients. Blood 2011, 117(3):936-941. 10.1182/blood-2010-06-288506, 20966170.
22. Guo M, Hu K-X, Liu G-X, Yu C-L, Qiao J-H, Sun Q-Y, Qiao J-X, Dong Z, Sun W-J, Sun X-D, et al. HLA-Mismatched Stem-Cell Microtransplantation As Postremission Therapy for Acute Myeloid Leukemia: long-Term Follow-Up. J Clin Oncol 2012, 30(33):4084-4090. 10.1200/JCO.2012.42.0281, 23045576.
23. Byrd JC, Mrózek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao KW, Watson MS, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461): presented in part at the 43rd annual meeting of the American Society of Hematology, Orlando, FL, December 10, 2001, and published in abstract form.59. Blood 2002, 100(13):4325-4336. 10.1182/blood-2002-03-0772, 12393746.
24. Ai H, Hu K, Sun Q, Li X, Guo M, Yu C, Qiao J, Qiao J, Liu G, Dong Z, et al. Microtransplantation with Decitabine and Cytarabine Improves Patient Outcomes in Myelodysplastic Syndromes. ASH Annual Meeting Abstracts 2012, 120(21):1709.
25. Morris ES, MacDonald KPA, Hill GR. Stem cell mobilization with G-CSF analogs: a rational approach to separate GVHD and GVL?. Blood 2006, 107(9):3430-3435. 10.1182/blood-2005-10-4299, 16380448.
26. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, et al. Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003, 21(24):4642-4649. 10.1200/JCO.2003.04.036, 14673054.
27. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, et al. Revised Response Criteria for Malignant Lymphoma. J Clin Oncol 2007, 25(5):579-586. 10.1200/JCO.2006.09.2403, 17242396.
28. Reagan JL FL, Nevola M, Quesenberry PJ. Random unrelated donor peripheral blood mononuclear cells (PBMC) stimulate cytolytic host T cell activity against leukemia [abstract]. Proceedings of the 104th Annual Meeting of the American Association for Cancer Research: 2013; 2013 Apr 6-10 2013, AACR: Washington, DC: Philadelphia (PA), Abstract nr 1252.
29. Venstrom JM, Pittari G, Gooley TA, Chewning JH, Spellman S, Haagenson M, Gallagher MM, Malkki M, Petersdorf E, Dupont B, et al. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med 2012, 367(9):805-816. 10.1056/NEJMoa1200503, 22931314.
30. Drabbels JJ, van de Keur C, Kemps BM, Mulder A, Scherjon SA, Claas FH, Eikmans M. HLA-targeted flow cytometric sorting of blood cells allows separation of pure and viable microchimeric cell populations. Blood 2011, 118(19):e149-155. 10.1182/blood-2011-06-362053, 21931111.
31. Mulder A, Kardol MJ, Arn JS, Eijsink C, Franke ME, Schreuder GM, Haasnoot GW, Doxiadis II, Sachs DH, Smith DM, et al. Human monoclonal HLA antibodies reveal interspecies crossreactive swine MHC class I epitopes relevant for xenotransplantation. Mol Immunol 2010, 47(4):809-815. 10.1016/j.molimm.2009.10.004, 19931911.